(Q34220059)

English

Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease (English)

1 reference

Europe PubMed Central

31 July 2017

autosomal dominant polycystic kidney disease

0 references

autosomal dominant polycystic kidney

1 reference

based on heuristic

inferred from title

author name string

Tom J G Gevers

1

1 reference

Europe PubMed Central

31 July 2017

Melissa Chrispijn

2

1 reference

Europe PubMed Central

31 July 2017

Jack F M Wetzels

3

1 reference

Europe PubMed Central

31 July 2017

Joost P H Drenth

4

1 reference

Europe PubMed Central

31 July 2017

publication date

4 April 2012

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

13

1 reference

Europe PubMed Central

31 July 2017

17

1 reference

Europe PubMed Central

31 July 2017

Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: a dichotomy of two ends of a spectrum.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368739

5 July 2018

Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368739

5 July 2018

Somatostatin analogues for treatment of polycystic liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368739

5 July 2018

Medical and surgical treatment options for polycystic liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368739

5 July 2018

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368739

5 July 2018

Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368739

5 July 2018

Evaluation of a gastrointestinal symptoms questionnaire

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368739

5 July 2018

Polycystic disease of the liver

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368739

5 July 2018

Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368739

5 July 2018

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368739

5 July 2018

Natural history of autosomal dominant polycystic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368739

5 July 2018

Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368739

5 July 2018

Autosomal dominant polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-13-17

21 January 2018

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-13-17

21 January 2018

Somatostatin analogues reduce liver volume in polycystic liver disease

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-13-17

21 January 2018

Effect of octreotide on polycystic liver volume

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-13-17

21 January 2018

Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-13-17

21 January 2018

Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-13-17

21 January 2018

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-13-17

21 January 2018

Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-13-17

21 January 2018

HIF1A signaling selectively supports proliferation of breast cancer in the brain

1 reference

https://api.crossref.org/works/10.1186%2F1471-2369-13-17

21 January 2018

Adult polycystic liver disease: is fenestration the most adequate operation for long-term management?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22475206

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Volume progression in polycystic kidney disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22475206

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22475206

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2369-13-17

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34220059&oldid=1516854598"